Pharmacokinetics and Pharmacodynamics of LY2951742 (Galcanezumab) in Healthy Subjects Following Subcutaneous Administration of LY2951742 (Galcanezumab) Solution in a Prefilled Syringe or an Autoinjector
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Galcanezumab (Primary)
- Indications Cluster headache; Migraine
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 23 Mar 2017 Planned End Date changed from 1 Feb 2017 to 27 Nov 2017.
- 23 Mar 2017 Status changed from completed to active, no longer recruiting.
- 08 Mar 2017 Status changed from active, no longer recruiting to completed.